Scott McLeod Named Adaptis Director of Sales Development

Wednesday, August 13, 2008 General News J E 4
SEATTLE, Aug. 13 Adaptis, a leading provider of businessprocess outsourcing solutions for health payers, today announced that it hasnamed Scott McLeod as director of sales development. Formerly the Adaptisdirector of marketing, McLeod is now responsible for increasing the company'ssales success by developing sales strategy, processes and training programs toincrease revenues and customer satisfaction. In his new role, he will workclosely with prospects and clients while collaborating with Product Managementand Marketing, in addition to Operations. McLeod will report to Jan E.Claesson, chief business development officer and senior vice president ofAdaptis.


Over his past seven years at Adaptis, McLeod has made significantcontributions to the company's success. "I am excited to be working with Scottin this new capacity," Claesson said. "As one of the most product andindustry-knowledgeable individuals at Adaptis, I am highly confident that withhis full attention now provided to our sales efforts, he will further Adaptis'market success."

About Adaptis

Adaptis provides comprehensive business process outsourcing solutions forhealth payers, focusing on Medicaid managed care, Medicare Advantage andcommercial health plans. Proven service performance and a client-centricaccount management approach underlie their administrative, medical managementand decision support services. Adaptis is headquartered in Seattle,Washington, with regional operations centers in Yakima, Washington andFrederick, Maryland. Its majority-owned subsidiary, Tela Sourcing Inc., isbased in Baltimore, Maryland, and has an ISO 9001:2000-certified facility inPune, India.


Cheryl Isen, Isen and Company, for Adaptis

(425) 222-0779

SOURCE Adaptis


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Prime Therapeutics Releases Annual Drug Trend Insi...
Amsterdam Molecular Therapeutics Reports Half Year...